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Abstract: 
Background:   Signs and symptoms of heart failure can occur at any time. Differences 
between acute heart failure (AHF) patients who present at nighttime vs. daytime and their 
outcomes have not been well studied.   Our objective was to determine if there are 
differences in baseline characteristics and clinical outcomes between AHF patients 
presenting during daytime vs. nighttime hours within an international, clinical trial. 
Methods: This is a post-hoc analysis of the RELAX AHF trial, which randomized 1,161 
AHF patients to serelaxin vs. placebo, both in addition to usual AHF therapy.  Pre-
specified end points of the primary trial were used: dyspnea, 60-day HF/RF (heart 
failure/renal failure) re-hospitalization or cardiovascular (CV) death, and 180-day CV 
death.  Both unadjusted and adjusted analyses for outcomes stratified by daytime vs. 
nighttime presentation were performed.   
Results: Of the 1161 RELAX-AHF patients, 775 (66.8%) patients presented during 
daytime and 386 (33.2%) at nighttime.  Baseline characteristics were largely similar, 
though daytime patients were more likely to be male, have greater baseline body weight, 
higher NYHA class, history of atrial fibrillation, and more peripheral edema than nighttime 
patients. No differences in dyspnea relief or 60-day outcomes were observed.  However, 
daytime presentation was associated with greater risk for 180-day CV death after 
adjustment (HR 2.28, 95% CI 1.34-3.86; c-statistic 0.82 (95%CI 0.78-0.86)). 
Conclusion: In this secondary analysis of the RELAX-AHF trial, baseline characteristics 
suggest daytime presenting patients may be more gradual worsening of chronic heart 
failure.  AHF patients who presented at night had less risk for 180-day CV death, but 
similar risk for 60-day CV death or re-hospitalization and symptom improvement as 
patients who presented during the daytime. 
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Introduction 
Symptoms and signs of acute heart failure (AHF) occur at any time, driving patients 
to seek care.  Observed differences in characteristics and outcomes between AHF patients 
presenting during daytime vs. nighttime hours suggest potential different 
pathophysiological mechanisms or differences in disease severity.1-3 Other acute 
cardiovascular processes, leading to myocardial infarction, myocardial ischemia, and 
sudden cardiac death occur more frequently in the early morning hours:4 Circadian rhythms 
may contribute to their respective disease mechanisms.5  
Attempts to better understand potential circadian interactions from acute heart 
failure (AHF) clinical trials have been limited by operational constraints: Patients are 
primarily enrolled during ‘working’ hours — Monday through Friday, 0800 to 1700.  
However, more recent trials narrowed the window of randomization, allowing greater 
scrutiny of potential circadian differences. Differences might spur further investigation into 
the pathogenic mechanisms; this may also have implications for clinical trial design. Thus, 
we conducted a post-hoc analysis of the RELAX-AHF trial to study potential differences in 
characteristics and outcomes for patients who present during daytime hours vs. nighttime 
hours and weekend/holidays.  
 
Methods 
This is a post-hoc analysis from the RELAX-AHF trial, whose design and main results have been 
previously reported. 6-9 Briefly, RELAX-AHF was an international, multi-center, randomized, 
double-blind, placebo-controlled trial that enrolled 1161 patients hospitalized for AHF.  The 
upper limit of randomization was 16 hours from first presentation to the hospital.  Patients 
received either serelaxin or matching placebo for 48 hours, both in addition to usual AHF care.  
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Per pre-specified eligibility criteria, all patients had shortness of breath, elevated natriuretic 
peptide levels, a chest x-ray with evidence of congestion, mild to moderate renal insufficiency 
(≥30 - ≤ 75 ml/min/1.73m2), a systolic blood pressure > 125 mmHg, and had received at least 40 
mg of intravenous furosemide (or equivalent) therapy.  All	clinical	trial	sites	were	IRB	or	Ethics	
Committee	approved	to	participate	in	RELAX‐AHF.		The	trial	was	registered	on	
clinicaltrials.gov,	NCT00520806.		The	original	RELAX‐AHF	study	was	sponsored	by	
Corthera	Inc,	a	Novartis	company.		Statistical	support	was	provided	by	Novartis,	however,	
the	authors	are	solely	responsible	for	the	design	and	conduct	of	this	study,	as	well	as	the	
drafting	and	editing	of	the	paper	and	its	final	contents.	
 
Differentiation of Weekend/Holidays and Daytime vs. Nighttime 
Across 11 countries, 96 sites contributed at least one patient to the trial. Saturday and Sunday 
were considered weekend for all countries except Israel, where Friday after noon and 
Saturday were considered weekend days.  National and regional non-working holidays 
days were also counted as a weekend day.  All other days were considered weekdays. 
Patients were classified based on time of randomization. 
Daytime and nighttime were determined based on previous studies: daytime (08h00 
to 19h59) and nighttime (20h00 to 07h59).2, 3 Patients were classified based on presentation 
time, not randomization for day vs. night analyses. Presentation was defined as the first 
recorded time of entry into the hospital system, most commonly via the ED. 
 
Outcomes 
The following pre-specified outcomes were analyzed:  1) Change in patient reported 
dyspnea assessed by the area under the curve representing the change from baseline 
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measured using a 100-mm visual analog scale (VAS) from baseline to day 5; the worst 
possible dyspnea VAS score was assigned following death or worsening heart failure. 2) 
cardiovascular (CV) death or HF/Renal Failure (RF) rehospitalization through day 60; and 
3) CV death through day 180.  Reasons for rehospitalizations through day 60 and cause of 
deaths through day 180 were adjudicated by an independent, blinded committee. The 
association of these outcomes with daytime vs. nighttime presentation as well as weekday 
vs. weekend/holiday randomization were explored.  
 
Statistical Analysis 
Data were analyzed using two separate categorizations: Presentation during 
daytime vs. nighttime and randomization on weekend/holidays vs. weekdays. 
Continuous variables are summarized as means and standard deviations, geometric 
means and associated 95% confidence intervals (CIs), or medians and interquartile range as 
appropriate; frequencies and percent are given for categorical variables. Groups were 
compared using ANOVA, t-test, Wilcoxon rank sum test or chi-square test as appropriate. 
Poisson regression was used to calculate and compare the estimated enrollment rates for 
weekend/holiday and working days.  
Both unadjusted and adjusted (using linear regression or Cox models as 
appropriate) analyses of outcomes between daytime vs. nighttime and weekday vs. 
weekend/holidays were performed. A multivariable linear regression model was developed 
in the placebo group for the dyspnea VAS AUC to day 5 using backwards selection, with a 
criterion for retention of P<0.10, from baseline patient clinical characteristics and routine 
laboratory measures.  The mean or mode within treatment group was substituted for 
missing continuous or categorical predictors, respectively. For those predictors where the 
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non-linear contribution of the association of a restricted cubic spline transformation with 
the outcome was significant (P<0.10), the non-linear transformation with the lowest 
Akaike’s Information Criterion was chosen from among a dichotomized, trichotomized, 
linear spline or quadratic or cubic polynomial transformation. The effects of daytime v. 
nighttime presentation and weekday v. weekend/holiday randomization on the outcome 
were then adjusted for those variables associated with the outcome in the placebo group. 
Multivariable Cox regression models for 60-day HF/RF rehospitalizations or CV death and 
180-day CV mortality were developed using similar methodology.  Baseline covariates 
found to be prognostic of each outcome variable were included in the adjusted models, 
with appropriate transformations for non-linear associations. Covariates found to be 
prognostic of dyspnea VAS AUC to day 5 were age, US-like, weight, body temperature 
(linear spline at 36.3), dyspnea on exertion, hypertension, mitral regurgitation, history of 
atrial fibrillation or flutter, alkaline phosphatase, sodium, log2 troponin T (linear spline at -
4.9), dyspnea VAS score (cubic), and uric acid (cubic).  Covariates found to be prognostic 
of 60-day CV death or HF/RF rehospitalization were white race, NYHA class 30 days 
before, systolic BP, respiratory rate, number of HF hospitalizations in the past year, 
orthopnea (ordinal), asthma or bronchitis or COPD, hyperthyroidism, lymphocytes %, 
BUN, phosphate (cubic), sodium, and total protein (linear spline at 68).  Covariates found 
to be prognostic of CV mortality through day 180 were US-like, systolic BP, orthopnea 
(ordinal), angina, hyperthyroidism, mitral regurgitation, atrial fibrillation/flutter at 
screening, lymphocytes %, white blood cell count, BUN, sodium, potassium, calcium, total 
protein, log2 troponin T, and log2 NT-proBNP.  “US like” is defined by the following 
countries: United States, France, Netherlands, Israel, Spain, Germany, Italy, and Poland. 
Non-US like includes patients from Argentina, Hungary, and Romania. 
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For consistency, we have used the same multivariable models for each secondary 
RELAX-AHF manuscript.  For each model, adjusted R2 (for continuous outcome) or C-
index (for time-to-event outcome) are reported, given the potential risk of overfitting. 
Thus, adjusted R2 values from five-fold cross-validations are presented. C-indexes from 
five-fold cross-validations are also presented.” 
 
Results 
All 1161 patients enrolled in the RELAX-AHF trial comprised the cohort for 
analysis.7 Of those, 775 (66.8%) patients presented during the daytime and 386 (33.2%) at 
nighttime. Figure 1 shows the numbers of patients who presented at each hour.  
Baseline characteristics, stratified by daytime vs. nighttime presentation, are 
summarized in Table 1. Overall, daytime and nighttime patients were similar, with the 
following exceptions: nighttime patients were more likely to be women, had a lower body 
weight, were more likely to have been enrolled in Eastern Europe, and be in NYHA Class 
II in the month prior to presentation, and had a lower prevalence of peripheral edema 
compared to daytime patients. Nighttime presentation was also associated with a slightly 
higher high sensitivity troponin level, but less atrial fibrillation at time of screening, less 
history of CRT implants, and less beta blocker use. Time from presentation to 
randomization was longer in nighttime patients. (Supplemental Figure 1) 
 
Working Days vs. Weekend/Holidays Randomization 
A much smaller number of patients were enrolled on the weekend/holidays (n=106) 
compared to weekdays (n=1055). (Supplemental Figure 1b) Enrollment during weekdays 
was over 4 fold greater than weekend/holidays (enrollment rate ratio = 4.2 (95%CI 3.44-
10	
	
5.13). Baseline characteristics are presented in Supplemental Table 1 and were largely 
similar between groups.  Of note, patients enrolled during the week were younger by 
almost 4 years, with significantly lower proportion of women enrolled. Weekend 
enrollment was greatest in Eastern Europe.  Weekday patients were more likely to have an 
EF < 40%, more NYHA Class III (but less Class II and IV), and more devices 
implantations.  They were also more likely to have edema at baseline. 100% of weekend 
patients presented with rales vs. 94% of weekday patients.  The time from presentation to 
randomization was similar for both groups. 
 
Timing of Presentation or Randomization and Relationship to Outcomes 
Daytime vs. Nighttime 
There were no differences in dyspnea improvement (VAS AUC through 5 days) or 60-day 
HF or RF re-hospitalization by day or nighttime presentation.  However, daytime patients 
were at an increased risk of 180-day CV death, which approached statistical significance 
without covariate adjustment (HR 1.62, (95% CI 0.99-2.64), p = 0.0546; c-statistic 0.55 
(0.50-0.59)), but was statistically significant after multivariable adjustment (HR 2.28, (95% 
CI 1.34-3.86); c-statistic 0.82 (95%CI 0.78-0.86) p=0.0023).  Survival curves are shown in 
Figure 2.  
 
Weekday vs. Weekend/Holidays 
Although limited by smaller numbers, no significant differences were seen in any of the 
three unadjusted analyses, though greater differences in dyspnea were seen in 
weekend/holiday patients compared to day vs. night. (Table 2b)  After multivariable 
adjustment, weekday patients had significantly less improvement in dyspnea (mean 
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difference -458.6 mm-hour, 95% CI -922.6-5.5, p=0.0528) compared to weekend/holiday 
patients.  In terms of mortality and re-hospitalization, weekday patients experienced 
significantly less CV death or HF/RF re-hospitalization through day 60 (HR 0.55, 95% CI 
0.34-0.91,p=0.0194) c-index 0.74 (0.70-0.78)),  however, no differences in 180-day CV 
death were seen. 
 
Treatment Effect by Daytime vs. Nighttime Presentation or Weekend/Holidays vs Weekday 
Randomization 
A similar analysis stratifying by treatment was also performed. No statistically 
significant interactions between treatment (serelaxin vs. placebo) and either daytime versus 
nighttime presentation or workday versus weekend/holiday enrollment were observed for 
any of the three outcomes examined (data not shown).   
 
Discussion 
In this post-hoc analysis from RELAX-AHF, approximately two thirds of enrolled 
patients presented during daytime hours and 90% were randomized on a weekday.  
Overall, we found: 1) Nighttime patients were at significantly less risk for 180-day CV 
death; 2) Weekend/holidays patients had greater dyspnea improvement through 5 days; 
however, 3) Weekend/holidays patients were at greater risk for 60-day CV death or HF/RF 
re-hospitalization; they were not at greater risk for 180-day CV death.  No treatment 
interactions were observed.  Unsurprisingly, most trial patients were enrolled during 
weekday business hours.  A longer time from presentation to randomization occurred for 
nighttime patients though there was no difference between weekday and weekend/holidays 
patients.  
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Within the limitations of a clinical trial population, timing of presentation may 
identify a different phenotype of AHF.10, 11   While baseline characteristics were similar 
overall, nighttime patients were more likely to be female, lighter in weight, have NYHA 
class II symptoms vs. Class III, less atrial fibrillation, and less peripheral edema, though 
with slightly higher high-sensitivity troponin T levels. This suggests nighttime patients 
may be more rapid onset vs. a gradually worsening chronic HF phenotype.  Our analysis 
suggests nighttime patients are a lower risk group, despite the median NT-proBNP of 5228 
ng/L. 
This finding of lower baseline risk of nighttime supports previous registry work 
from the Japanese ATTEND registry (4) where better outcomes were reported for 
nighttime presenting patients. However, in ATTEND, once adjusted for presenting SBP, 
the differences were no longer significant. In a different study by Minami et.al., significant 
SBP differences between daytime and nighttime patients were observed, suggesting 
distinct phenotypes of AHF may present during the day vs. night.  We did not find any 
differences in baseline SBP in our analysis.  An older study exploring the chronobiology of 
acute pulmonary edema,1 found the majority of acute pulmonary edema cases occurred at 
night. While the explanatory mechanism remains unclear, the authors suggested the 
potential impact of lying flat with subsequent increased venous return as a potential 
precipitant in at-risk individuals.  Thus, patients presenting at nighttime seem more likely 
to have a clinical presentation of acute pulmonary edema whereas those presenting during 
daytime are more likely to have fluid overload and peripheral edema as the main cause of 
decompensation. Although these patients may appear more acutely ill at time of 
presentation vs. slowly worsening chronic HF, paradoxically, these patients who present 
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with higher SBP may have lower longer term risk. This may also explain their worse 
prognosis as daytime patients may be a more gradual worsening chronic HF phenotype.12 
Patients enrolled during nighttime had a longer time from presentation to 
randomization. This is probably related to reduced research staffing during night times. 
This relative lag time at night compared to daytime may be important if earlier initiation of 
therapies is found to be beneficial. It must be, however, noted that no interaction between 
time from presentation to treatment and outcomes was found in two recent trials.13, 14  
Of note, no differences in timing of presentation to randomization occurred on 
weekend/holidays, when study staff might also be less available. Discordant signals of 
greater dyspnea improvement in weekday patients, but more CV death or HF/RF re-
hospitalization suggest a weak or absent relationship between symptom improvement and 
60-day outcomes.  Despite less risk for 60-day outcomes, no improvement in 180-day CV 
death was observed for weekend/holidays patients.  In OPTIMIZE HF, approximately 22% 
of patients were hospitalized on a weekend.  No differences in 60-90 day mortality or 
rehospitalizations were observed.15 
Overall, this study suggests future AHF trials should enroll AHF patients 
irrespective of day or night to maximize generalizability. 
 
Limitations: 
As a post-hoc analysis, unmeasured confounders may be present due to the lack of 
randomization between groups, despite their similar baseline characteristics and adjusted 
analysis.  As this is a clinical trial population with strict eligibility criteria, these findings 
should not be applied to the general AHF population. External validation of our findings in 
a more general AHF population is needed. It is worth highlighting that certain high risk 
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features were excluded from this clinical trial population, such as significant anemia, 
significant arrhythmias, severe infections, ACS, patients with significant underlying valve 
disease, transplant patients, vented patients, or those requiring inotropic therapy – all 
known markers of risk.  At the same time, only patients with mild to moderate renal 
insufficiency were included and only those with elevated natriuretic peptide levels, along 
with significant symptoms at rest or with minimal exertion.  A particular criterion was the 
elevated SBP > 125 required for RELAX AHF; specifically for our study, the mean SBP 
was 142mmHg (SD 17).  When compared to other published registries such as ADHERE, 
OPTIMIZE HF, and EurObservationl, our average SBP is remarkably similar (ADHERE 
mean SBP 144mmHg (SD 32.6),16 OPTIMIZE HF 142.6mmHg (33.2),17 and 
EurObservational 133mmHg (29).18 Overall, less heterogeneity of a clinical trial 
population as well as similarity in baseline characteristics supports our hypothesis 
generating findings vs. attribution to other co-morbid conditions or precipitants.  
 
Conclusion 
In this post-hoc analysis from RELAX-AHF 2, nighttime patients presented with 
unique clinical characteristics compared to daytime patients; most notably less peripheral 
edema.  They were also associated with lower risk for 180-day CV death than daytime 
presenting patients. Although further work is needed to confirm these findings, especially 
from a mechanistic standpoint, trial enrollment strategies to capture these patients are 
needed to ensure generalizability of study findings.  
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